$ALHC

KAO JOHN E sold $5.9M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $19.86 ($19.81–$20.65, $5.92M total) across 2 trades on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jul 14, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
high confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CEO through a pre-arranged 10b5-1 plan; absent other news, it typically does not change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article does not disclose total insider ownership changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or remaining plan schedule.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-14 after-hours; transaction dated 2026-07-10.

Background

The article is a SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralHigh confidence
Context

CEO John E. Kao sold $5.9M of Alignment Healthcare shares via a 10b5-1 plan, with 298,000 shares sold at $19.81–$20.65.

Expected impact

Likely limited near-term impact; any effect is typically short-lived unless accompanied by other negative disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly marked as pre-arranged 10b5-1, with no accompanying operational, regulatory, or financial guidance changes in the text.

Market effects

No sector-level read-through is provided; this is company-specific insider selling.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can reflect planned liquidity needs rather than bearish expectations, so the market may ignore it.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • John E. Kao

    CEO and reporting person who sold shares via a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Alignment Shares Tumble on Rising Medical Costs

Alignment Healthcare (ALHC) shares fell 16% after executives cited rising medical costs and claims system issues. CEO John Kao noted the company is addressing these challenges. Despite a 47% drop in the past year, the company maintained its revenue guidance. TD Cowen reiterated a Buy rating with a $21 price target. Alignment is expanding its network with Hoag Memorial Hospital.

$ALHCMed

ALHC Stock Slides As Legal And Cost Pressures Mount

Alignment Healthcare Inc. (ALHC) shares fell 3.61% on September 18, 2026, due to investor concerns over Medicare Advantage reimbursement and regulatory pressures. The stock has dropped significantly from $13–$14 to around $8.35, with technical damage and high volatility. Management cited Q3 medical cost headwinds and additional investments, while a whistleblower alleged expense misclassification, leading to legal probes. Insider selling and weak sentiment have further pressured the stock.

$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.